1. Academic Validation
  2. Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway

Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway

  • Oncol Rep. 2017 Aug;38(2):1233-1239. doi: 10.3892/or.2017.5779.
Ran Tao 1 Wen-Yi Sun 2 De-Hai Yu 3 Wei Qiu 4 Wei-Qun Yan 2 Yan-Hua Ding 5 Guang-Yi Wang 4 Hai-Jun Li 1
Affiliations

Affiliations

  • 1 Institute of Translational Medicine, the First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
  • 2 Department of Clinical Pharmacy and Pharmaceutical Management, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China.
  • 3 Cancer Center, the First Hospital of Jilin University, Changchun, Jilin 130061, P.R. China.
  • 4 Department of Surgery, the First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
  • 5 Phase Ⅰ Clinical Research Center, the First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Abstract

The function of sodium cantharidinate on inducing hepatocellular carcinoma cell Apoptosis was investigated for the first time. Sodium cantharidinate inhibits HepG2 cell growth mainly by LC3 Autophagy pathway. MTT results show that sodium cantharidinate effectively inhibits the proliferation of HepG2 cells in a dose- and time-dependent manner and induce cell Apoptosis by Caspase-3 activity. The further western blotting and FACS detection show that sodium cantharidinate initiates HepG2 cell Autophagy program by LC3 pathway. Autophagy-specific inhibitor 3-MA reduce sodium cantharidinate-induced Caspase-3 activity and HepG2 cell Apoptosis. Silence of the LC3 gene in HepG2 cell lines also reduce sodium cantharidinate-induced cell Apoptosis. Collectively, our data indicate that sodium cantharidinate induces HepG2 cell Apoptosis through LC3 Autophagy pathway. Sodium cantharidinate has potential for development as a new drug for treatment of human HCC.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12466
    ≥98.0%, Caspase-3 Inhibitor